Platform for myocardial infarct MRI and delivery of therapeutics

心肌梗塞 MRI 和治疗递送平台

• 批准号: 8395201
• 负责人: ERIC T. AHRENS
• 金额: $ 37.92万
• 依托单位: CELSENSE, INC.
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-08-20 至 2013-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8395201
• 关键词: Adoption; Affect; Area; Biocompatible Materials; Cardiac; Cells; Cicatrix; Clinical; Computer software; Cues; Data; Detection; Development; Emulsions; Engineering; Family suidae; Fluorine; Fluorocarbons; Goals; Gold; Heart; Heart failure; Image; Imagery; Imaging Device; Imaging technology; Infarction; Inflammation; Inflammatory; Injection of therapeutic agent; Label; Left ventricular structure; Location; Magnetic Resonance Imaging; Manuals; Methods; Modeling; Myocardial Infarction; Myocardium; Persons; Procedures; Process; Proteins; Pump; Reagent; Route; Signal Transduction; Site; Stem cells; Therapeutic; Tissues; Translations; United States; Validation; Visualization software; base; clinically relevant; interest; intravenous injection; macrophage; response; standard of care

Myocardial infarction (MI) afflicts more than one million persons per year in the United States alone. MI results in permanent left ventricle (LV) scarring that causes diminished pump efficiency and, commonly, heart failure. Towards reduction or elimination of scarring, there is increasing interest in reparative biological materials, such as cells and proteins, that are introduced into the affected region of the LV early after MI. We believe that such an approach will eventually become part of a standard of care. The most promising route for the delivery of such materials is direct LV injection (DLVI). Thus far, the utility of DLVI has been hampered by the lack methods for accurate spatial targeting of affected tissue. This has greatly impeded clinical translation of promising materials. The goal of this project is to devise cutting edge imaging tools to visualize infarcted regions using MRI.

仅在美国，每年就有超过一百万人患有心肌梗塞 (MI)。 MI 会导致永久性左心室 (LV) 疤痕，从而导致泵效率降低，并且通常会导致心力衰竭。为了减少或消除疤痕，人们越来越关注在心肌梗死后早期将细胞和蛋白质等修复性生物材料引入左心室受影响区域。我们相信这种方法最终将成为护理标准的一部分。此类材料最有前途的输送途径是直接左心注射 (DLVI)。迄今为止，DLVI 的实用性因缺乏对受影响组织进行精确空间定位的方法而受到阻碍。这极大地阻碍了有前景材料的临床转化。该项目的目标是设计尖端成像工具，利用 MRI 可视化梗塞区域。